Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.54 |
| ▸ | MME | P08473 | 4/20 | 0.53 |
| ▸ | ACE | P12821 | 4/20 | 0.53 |
| ▸ | CPA1 | P15085 | 4/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.51 |
| ▸ | IL1RN | P18510 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL12475338 | 0.88 | MME (0.66) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30538862 | 0.86 | LTA4H (0.61) | LTA4HMMEACECPA1ACE2 | |
| Trifluoroacetic Acid SCHEMBL30168522 | 0.82 | MME (0.53) | MME | |
| Trifluoroacetic Acid SCHEMBL30168523 | 0.82 | MME (0.53) | MME | |
| SCHEMBL30538840 | 0.79 | IL1RN (0.60) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL25000465 | 0.78 | POLB (0.58) | MMEACE | |
| SCHEMBL19316083 | 0.78 | MMP1 (0.55) | MMEERAP2IL1RNERAP1 | |
| SCHEMBL25901510 | 0.77 | MME (0.62) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL28771144 | 0.77 | TACR1 (0.57) | — | |
| SCHEMBL28569722 | 0.77 | CTSC (0.48) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518088-B2 | Peptide-phospholipid conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20130345117-A1 | PEPTIDE-PHOSPHOLIPID CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012108990-A2 | PEPTIDE-PHOSPHOLIPID CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345117-A1 | PEPTIDE-PHOSPHOLIPID CONJUGATES | LPAR3, SSTR3, NPY2R | LTA4H 1146/4885MME 1999/4885ACE 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.